AAPL 207.19 -0.19 (-0.09%)MSFT 129.17 +4.11 (+3.29%)FB 193.85 +2.77 (+1.45%)ZNGA 5.58 0 (+0.09%)NVDA 191.18 -0.12 (-0.06%)WBA 53.48 -0.04 (-0.07%)GOOG 1256.05 -0.4 (-0.03%)PIH 5.25 -0.05 (-0.94%)
AAPL 207.19 -0.19 (-0.09%)MSFT 129.17 +4.11 (+3.29%)FB 193.85 +2.77 (+1.45%)ZNGA 5.58 0 (+0.09%)NVDA 191.18 -0.12 (-0.06%)WBA 53.48 -0.04 (-0.07%)GOOG 1256.05 -0.4 (-0.03%)PIH 5.25 -0.05 (-0.94%)

Cash Flow ANAB Quote AnaptysBio

All | Income Statement | Balance Sheet | Cash Flow | Retained Earnings | PPE Schedule | Intangible and Goodwill Schedule
Year 201420152016
NetIncome -4 -30 -62
Depreciation 0 0 0
DeferredIncomeT 0 0 0
StockBasedCompe 1 4 10
AccountsReceiva 0 0 0
InventoryCS 0 0 0
AccountsPayable 1 2 7
OtherWorkingCap -7 4 2
OtherNonCashIte 1 2 1
NetCashProvided -9 -19 -49
InvestmentsInPP 0 0 -1
AcquisitionsNet 0 0 0
PurchasesOfInve 0 -291 -348
SalesMaturities 0 48 206
PurchasesOfInta 0 0 0
OtherInvestingA 0 0 0
NetCashUsedForI 0 -243 -142
DebtIssued 10 0 0
DebtRepayment 0 0 -7
CommonStockIssu 0 294 230
CommonStockRepu 0 0 0
DividendPaid 0 0 0
OtherFinancingA -1 -2 0
NetCashProvided 9 292 223
NetChangeInCash 0 30 32
CashAtBeginning 52 51 81
CashAtEndOfPeri 51 81 114
AnaptysBio Inc. income statement is the only one that provides an overview of company sales and net income
The reasoning behind the adjustment, however, is that free cash flow is meant to measure money being spent right now, not transactions that happened in the past. This makes AnaptysBio Inc. FCF a useful instrument for identifying growing companies with high up-front costs, which may eat into earnings now but have the potential to pay off later.